ONCOLOGIST - Peeref

Note: The following journal information is for reference only. Please check the journal website for updated information prior to submission.

Journal Title

ONCOLOGIST

ISSN / eISSN

1083-7159 / 1549-490X

Aims and Scope

The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.

Subject Area

ONCOLOGY

CiteScore

10.10

View Trend

CiteScore Ranking

Category	Quartile	Rank
Medicine - General Medicine	Q1	#57/830

Web of Science Core Collection

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

Category (Journal Citation Reports 2023)	Quartile
ONCOLOGY - SCIE	Q1

H-index

145

Country/Area of Publication

UNITED STATES

Publisher

AlphaMed Press

Publication Frequency

Monthly

Year Publication Started

1996

Annual Article Volume

277

Open Access

Contact

ALPHAMED PRESS, 318 BLACKWELL ST, STE 260, DURHAM, USA, NC, 27701-2884

Popular journals in the same field
Recent articles

Financial Toxicity: Unveiling the Burden of Cancer Care on Patients in Rwanda: (2023) Fidel Rubagumya, Brooke Wilson, Achille Manirakiza, Emmanuel Mutabazi, Diane A. Ndoli, Emmanuel Rudakemwa, Mary D Chamberlin, Wilma M Hopman, Christop...

A Rare Presentation of Aggressive Renal Cell Carcinoma and the Utility of Early Molecular Testing in Rapidly Progressing Malignancies: A Case Report: (2023) Daniel E McLoughlin, Nicholas Chevalier, Edwin Choy, Gregory M Cote, Xin Gao, Dejan Juric, Kerry L Reynolds

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study: (2023) Shilpa Gupta, Halley Costantino, Chiemeka Ike, Shaloo Gupta, Abhijeet Bhanegaonkar, Cathy Su, Sheena Thakkar, deMauri S Mackie, Geeta Devgan, Howard M...

Three-Week Versus 4-Week Schedule of nab-Paclitaxel in Patients With Metastatic Breast Cancer: A Randomized Phase II Study: (2023) Yaxin Liu, Guohong Song, Lijun Di, Hanfang Jiang, Ran Ran, Ruyan Zhang, Yan Zhang, Huiping Li

Toward More Accurate Preoperative Diagnosis of Vein Wall Invasion in Renal Cell Carcinoma Using Computer Vision: (2023) Valisha Shah, William Lotter

Promoting Inclusive Cancer Care: Beyond Medical Interpreters: (2023) Alex G Thomas, Alyx B Porter

The Landscape of US and Global Rare Tumor Research Programs: A Systematic Review: (2023) Christina Vivelo, Karlyne M Reilly, Brigitte C Widemann, Mary Frances Wedekind, Corrie Painter, Allison F O’Neill, Sabine Mueller, Olivier Elemento, A...

Incidence Trends, Clinicopathologic Characteristics, and Overall Survival Prediction in Retinoblastoma Children: SEER Prognostic Nomogram Analysis: (2023) Xiaohong Guo, Li Wang, Narasimha M Beeraka, Chunying Liu, Xiang Zhao, Runze Zhou, Huiming Yu, Ruitai Fan, Junqi Liu

Presence, Subtypes, and Prognostic Significance of Tertiary Lymphoid Structures in Urothelial Carcinoma of the Bladder: (2023) Guofeng Ma, Huiqing Jia, Guofang Zhang, Ye Liang, Xianning Dong, Guangming Fu, Xinsheng Wang, Haitao Niu

Challenging Rationality: Examining the Belief in Cure Among Patients With Advanced Incurable Cancers: (2023) Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva

Verified Reviews

Note: Verified reviews are sourced from across review platforms and social media globally.

It's really, really, really slow. I don't know what the editor is doing. They don't reply to emails either. The manuscript was submitted on October 14, 2022, and has been in the hands of the editor all this time without being sent for review. Later, we sent three reminder emails, and it was sent for review in December. Then, on January 1 and 23, 2023, the review comments should have been received, but it has been two months now and the manuscript is still with the editor. We have also sent several emails but have not received any replies.

2023-03-21

In the past two years, this journal had an impact factor of over 5 points. In 2019, it was still listed as a first-tier SCI journal and a second-tier journal by the Chinese Academy of Sciences. Why is it that the recently released SCI for 2021 does not show the impact factor? Is it truly excluded, or will there be a revised IF soon? We will have to wait and see, as there have been cases in the past where the IF for a journal was not initially calculated and later revised.

2021-07-02

View All Reviews

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More